tweetindex
PT

FierceBiotech ✓

@FierceBiotech · Washington, DC · joined 21 Dec 2008

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

102 606Followers
623Following
29 716Posts total
18.8KViews on collected posts

Posts recentes

A study published in Science showed that giving psilocybin before chemotherapy prevented the development of pain hypersensitivity caused by neurotoxic chemotherapies, with protection maintained up to 8 months in mice. https://t.co/ubMtNeqZ0q 767 views · 5 likes · 0 reposts · 0 replies Open on X →
Noubar Afeyan has built a career around an unusual premise: Instead of waiting for the next biotech breakthrough, create the conditions for one. The Flagship Pioneering founder is a 2026 Fierce 50 Leadership honoree. 🔗 https://t.co/vVRn0W1emH @FlagshipPioneer #Fierce50 https://t 796 views · 2 likes · 0 reposts · 0 replies Open on X →
By targeting large unmet markets in hair loss and endometriosis with a direct-to-consumer approach, Absci is on a mission to become a household name. https://t.co/tzOcIXS0ia 9.5K views · 35 likes · 2 reposts · 0 replies Open on X →
The 2026 Fierce 50 is live. Among this year’s honorees are scientists, biotech leaders and organizations pushing into new areas of drug development, diagnostics and patient care. https://t.co/jGb5ppJjBV https://t.co/8C55jDZ3J3 3.6K views · 5 likes · 1 reposts · 1 replies Open on X →
@FierceBiotech New modalities only reach patients if there are people who can take them from bench to GMP production. On ATMP growth in the Netherlands and the talent it demands: https://t.co/gnLFZOKcZo 24 views · 0 likes · 0 reposts · 0 replies Open on X →
@FierceBiotech rare disease tRNA plays are a small market until one hits and becomes the platform everyone retroactively calls obvious 69 views · 1 likes · 0 reposts · 0 replies Open on X →
With mRNA back in the spotlight, tRNA shows potential to treat genetic disease https://t.co/TA9y64vG1l 4.1K views · 25 likes · 2 reposts · 2 replies Open on X →

Em comparação com contas do mesmo porte

7 posts dos últimos 90 dias, ao lado da faixa de 100K–1M seguidores. abaixo dos pares tanto em alcance quanto em engajamento.

Mediana de visualizações796esta conta5 983mediana para 100K–1M
Alcance, %0.78%esta conta1.49%mediana para 100K–1M
Engajamento, %0.41%esta conta0.93%mediana para 100K–1M
MétricaEsta contaMediana para 100K–1MProporção
Mediana de visualizações por post7965 9830.13×
Alcance (visualizações ÷ seguidores)0.78%1.49%0.52×
Taxa de engajamento0.41%0.93%0.44×

Outras contas desta faixa →   Comparar com outra conta →   Como estas referências são construídas →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

4.1K28 Aug
69
2429 Aug
3.6K1 Sep
9.5K2 Sep
7964 Sep
767

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.71%28 Aug
1.45%
0.00%29 Aug
0.20%1 Sep
0.41%2 Sep
0.25%4 Sep
0.65%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.

What the audience does

Likes70.2%73 in total
Reposts4.8%5 in total
Replies2.9%3 in total
Quotes1.9%2 in total
Bookmarks20.2%21 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Contas semelhantes